Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

 Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform and small molecule drug discovery capabilities

• Financing supports expansion of potentially best-in-class ATR inhibitor and first-in-class highly selective Polθ inhibitor programs by enabling clinical development in multiple tumor settings and biological backgrounds of single agent and combination therapies

CAMBRIDGE, UK and NEW YORK, USA, 27 July 2021: Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, today announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...